Drug | No. of pregnancies exposed to drug | Live births related to exposed drug | Elective terminations | Spontaneous 1st trimester loss | Spontaneous 2nd/3rd trimester loss | Major malformations | Minor malformations | No. Studies |
---|---|---|---|---|---|---|---|---|
Prednisolone | 176 | Min 110 | 0 | 1 | 1 | 9 | 1 | 11 |
Methotrexate | 15 | Min 5 | 2 | 2 | 0 | 0 | 0 | 5 |
Leflunomide | 80 | Min 78 | 1 | 0 | 0 | 7 | 63# | 8 |
Sulphasalazine | 57 | Min 1 | 0 | 0 | 0 | 0 | 0 | 3 |
Azathioprine | 210 | 208 | 14 | 4 | 5 | 8 | 0 | 7 |
HCQ | 189 | Min 142 | 0 | 14 | 0 | 10 | 0 | 8 |
Biologics (Inflix, etan, ada)* | 118 | 88 | 10 | 29 | 4 | 0 | 4 | 1 |
Rituximab | 155† | 92 | 28 | 33 | 3 | 3** | 1 | 3 |
*No increased risk of minor malformations compared to control group |
↵* Data is analysed from Verstappen (2010) only.
↵† 29/155 pregnancies were in RA patients.
↵** One of the major congenital abnormalities (Turners syndrome) was diagnosed pre-administration of RTX.
↵# No increased risk of minor malformations compared to control group. BSRBR: British Society for Rheumatology Biologics Registers.